
usd dec pm et
summari compani manufactur scientif analyt equip liquid chromatographi
mass spectrometri thermal analysi product
price-to-earnings oper ep
risk assess reflect strong brand power
liquid chromatographi mass spectrometri thermal
analysi market gener highest margin
industri advantag partial off-set howev
highli competit marketplac depend
pharmaceut budget revenu
drug firm produc volatil sale swing
instrument maker budget manufactur
need unexpectedli face larg cut also carri
product risk escal tariff environ
view product capac locat
jan ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
dec pm stock trade
grow year-to-d
revenu thru fell yoy put firm
track first annual sale declin sinc
primari culprit year
weak demand intern market
includ europ sale yoy
china flat yoy experienc
healthi growth revenu
first nine month increas yoy
addit soft intern demand key
challeng think face escal
tariff exacerb larg mismatch
product capac
 custom locat
sale like mean much
suppli chain final sale face
sale from/to largest foreign market
ytd adjust ep grew yoy
view sustain long term
howev -- growth came billion
share repurchas last year
cash drawn billion
versu billion exclud
incom fell yoy pre-tax margin drop
mix view follow
recent news phase one trade deal
resolut china
impact compani posit although
uncertainti remain detail
agreement held sever disadvantag
high tariff environ view
longer come clear neg
manufactur concentr singl
sourc compon lack cross-sel
help strong brand name
analyt instrument yet neutral
view share sinc expect
halt revenu growth compani
revenu decreas year-to-d thru
revenu growth
still expect revenu
contract yoy flat
vs earlier call revenu
target ep estim
line histor forward price-to-earnings averag
risk view halt -china
trade resolut put risk current
agreement strong rebound econom
growth europ china
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
senior vice presid
corpor overview water corpor specialti measur compani develop tool
liquid chromatographi lc mass spectrometri ms thermal analysi ta tool primarili
serv research develop manufactur tester life materi food scienc
compani also sell softwar platform use oper machin analyz result data well
servic laboratori workflow optim
liquid chromatographyi standard scientif techniqu separ identifi constitu
compon variou compound molecular level lc allow research analyz chemic
physic biolog composit materi liquid chromatographi often use tandem
mass spectrometri use elucid structur chemic properti molecul
measur mass molecul convert ion ms also use identifi
quantifi amount specif compound present sampl
thermal analysi tool allow research analyz compound react temperatur chang
especi electr properti chang physic properti fluctuat weight flow
characterist thermal analysi use help research predict compound perform
move laboratori state applic state molecul drug
perform blood rather lab bench suitabl stabil fine
chemic pharmaceut water polym metal viscou liquid use industri applic
consum good health care product better understood thermal analysi
import user product research pharmaceut life scienc
industri scientist use lc ms ta extens analyz compound molecular level
help better understand diseas discov new drug develop manufactur method assur
potenc puriti new pharmaceut tool also use varieti applic
analyz content food beverag nutrit label complianc test water
air sampl meet safeti puriti regul within environment test busi well
applic industri chemic consum product univers research
institut government agenc food drug administr fda
environment protect agenc epa foreign counterpart also frequent user
import aspect busi understand instrument sale vs consum servic
sale instrument perman fixtur laboratori manufactur site come rel
larg up-front cost convers consum lower-cost product use analyz
instrument typic replac regular interv relationship instrument
consum somewhat analog razor razor-blad model custom typic purchas
rel small number instrument continu order larg volum consum
life machin analyz thousand sampl instrument sale often lead recur
softwar servic contract revenu well way singl instrument sale often lead durabl
long-term sale lower-cost product mitig cyclic instrument sale
revenu came instrument servic consum
breakdown sale geographi follow asia america europ
similar sale growth sale growth mainli driven asia sale
yoy particularli china sale yoy wit double-digit growth across
product custom segment howev first nine month record china sale
compar prior-year period subdu revenu growth compar
yoy growth period previou year explain slowdown econom
activ china view wat europ sale grew america sale
challeng econom condit europ translat slower sale growth first nine month
us expect cautiou tone wit custom seen far remain
competit landscap due often high-tech innov natur custom
must also frequent innov product meet evolv custom need stay competit
spent revenu research develop competit
market tool intens rival compet primarili basi product innov
perform reliabl servic price lc ms market competitor includ larg life
scienc tool servic firm shimadzu thermo
fisher scientif thermal analysi market princip competitor includ
netzsch-geraetebau malvern panalyt anton-paar
financi trend sale increas repres three-year
compound annual growth rate compound-annual-growth-rate adjust ep rose
three-year compound-annual-growth-rate grown ep materi faster revenu combin
improv oper margin share count reduct adjust pre-tax incom margin improv
major gain come declin sg expens
margin gross profit margin remain rel constant
respect compani also execut net share repurchas worth
reduc share count three-year period maintain low debt
rel earn net debt/ebitda septemb
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
bullish sinc novemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
lst sub-industri
next year expect earn growth
remain posit slow sharpli
rate achiev posit
earn growth view
healthi fund public medic research
demand growth emerg market expect
factor balanc slower
biopharmaceut spend growth
neg effect trade tariff
budget nation institut
nih grow rapidli
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih
fy sep budget grew vs prior
year follow growth
fy fy respect mark
major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
expect lst firm
continu see strong demand
publicly-fund lab
prolifer advanc health care around
world also continu drive demand
growth lst firm trend
remain particularli strong china
emerg market rapidli grow middl
class gain access advanc health
care drive suppli need new expand
medic research lab facil
estim trend drove growth
lst sub-industri sale
asia-pacif region expect
continu posit long-term driver
contrast strong demand growth
expect publicly-fund client think
biopharmaceut firm moder
 spend growth year ahead
estim total
spend
biopharmaceut compani grew
annual averag expect slow
howev
mani biopharmaceut firm look limit
spend growth off-set recent
revenu headwind patent expir
public scrutini high drug price larg
swath biopharma typic flow
lst firm suppli depart
research tool softwar contract servic
accordingli think slowdown
biopharma growth reduc tailwind
mani lst firm receiv
client group recent year
final recent escal trade tariff
neg impact lst earn
growth view expect
continu analyt
instrument maker lst sub-industri
global suppli chain see
strong oper profit growth
first half brought lower profit
mani busi think shift
relat escal tariff impos
 -china trade
soften demand -made
instrument china rais product
cost instrument maker limit
suppli chain flexibl end sight
current trade disput expect tariff
continu pressur sale growth
oper margin sub-industri
year-to-d septemb
 life scienc tool
servic rose broader
base index
five-year market price perform dec
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
hold drop target
ep estim unchang forward price-to-earnings averag suffer
bp yoy drop adjust oper margin think indic
difficulti navig escal tariff key issu view larg
mismatch versu peer product capac estim
 custom locat sale like
mean much suppli chain final sale face rise border tariff
particularli part order sale from/to largest foreign market china
sale sale fell yoy disadvantag lack
diversif beyond analyt instrument view think peer
gener stickier custom cross-sel across broader segment dri
powder buyback also near low could serv reduc
ep boost repurchas gener /colin scarola
et cfra maintain hold opinion share water corpor
drop target ep
estim -- line histor forward price-to-earnings averag ep
vs consensu lower ep estim
revenu fell yoy mark
first sale declin sinc primari driver major slowdown asia
sale grew flat yoy sharp drop
europ sale grew fell yoy addit
adjust pre-tax margin fell sharpli versu
lead yoy drop adjust pre-tax incom yoy drop
per share basi due net share buyback last year
diverg non-gaap ep growth yoy due exclus
restructur cost versu expect reli
heavili buyback restructur adjust meet ep growth
guidanc /colin scarola
analyst research note compani news
et cfra lift sell opinion share water corpor hold
lift target ep estim
line five-year histor forward price-to-earnings averag
maintain ep estim
think one best-posit name within life scienc
sphere benefit resolut phase-on deal
china although uncertainti remain detail agreement
view risk relat revenu slowdown america due
cautiou tone wit custom europ due challeng
econom condit yet risk could off-set renew growth
momentum china wit double-digit growth across product
custom segment experienc subdu growth yoy
first nine month thu prefer neutral see clear
posit neg wat financi perform /sel hardi
pm et cfra maintain sell opinion share water corpor
keep target ep estim --
histor forward price-to-earnings averag lower ep estim
start ep vs
met consensu revenu flat yoy miss guidanc
yoy drop instrument sale total weigh result america
revenu fell yoy sharp slowdown growth
instrument peer like continu gener strong growth
year though lead us believ lose market share due
view less flexibl manag tariff less sticki custom due
narrow product line ytd adjust pre-tax incom yoy
kept adjust ep grow ytd share repurchas
increas restructur adjust sustain sourc
ep growth view especi cash avail repurchas
low /colin scarola
pm et cfra maintain buy opinion share thermo fisher
scientif inc maintain price target
ep estim share major analyt instrument maker
sharpli today includ
around midday believ sell-off
partial relat ad chines firm export blacklist
monday increas tension trade war view
hurt global suppli chain instrument maker disagre
reaction share howev think compani global divers
product facil uniqu lack single-sourc suppli relationship
give much greater flexibl peer avoid tariff-driven cost
increas view advantag actual allow take signific
instrument market share smaller firm like etc
reli china revenu wherea gener
roughli sale /colin scarola
pm et cfra maintain sell opinion share water corpor
keep target ep estim --
histor forward price-to-earnings averag lower ep estim
maintain ep vs beat consensu
pharmaceut sale total grew yoy off-set declin
industri academ govern sale europ
revenu especi weak reflect slowdown econom growth
region view also think rel weak posit
trade war display pre-tax margin basi point
yoy driven view high concentr -focus product
sale intern mitig impact lower
sale higher cost repurchas see
sustain free cash flow declin co cash pile sinc
decemb also see sharp rise inventori bode poorli futur
pm et cfra lower opinion share water corpor sell
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
